Management of pneumococcal meningitis

Area of Science:

• Infectious Diseases
• Microbiology
• Pediatrics

Background:

• Antibiotic resistance in Streptococcus pneumoniae has increased, complicating pneumococcal meningitis treatment.
• Standard empiric therapy for bacterial meningitis in children over 1 month includes cefotaxime/ceftriaxone plus vancomycin.
• Treatment requires adjustment based on antimicrobial susceptibility testing.

Purpose of the Study:

• To review current treatment strategies for pneumococcal meningitis in light of rising antibiotic resistance.
• To discuss optimal therapeutic approaches for meningitis caused by resistant Streptococcus pneumoniae strains.
• To evaluate the role of adjunctive therapies and newer antimicrobial agents.

Main Methods:

• Review of current clinical guidelines and literature on pneumococcal meningitis treatment.
• Analysis of antimicrobial resistance patterns of Streptococcus pneumoniae.
• Evaluation of therapeutic options for meningitis with high-level cephalosporin resistance.

Main Results:

• Cefotaxime/ceftriaxone resistance in Streptococcus pneumoniae poses a challenge to standard empiric meningitis therapy.
• For strains with cefotaxime/ceftriaxone MIC >2 microg/ml, optimal treatment is not established, but adding rifampin is generally advised.
• Dexamethasone is the sole recommended anti-inflammatory agent.
• The empiric approach for vaccinated children remains unchanged.

Conclusions:

• Managing pneumococcal meningitis requires careful consideration of evolving antibiotic resistance patterns.
• Rifampin addition is a key strategy for treating meningitis caused by cephalosporin-resistant Streptococcus pneumoniae.
• Further research is needed on newer agents like quinolones for resistant infections.